Cystinosis Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Key Companies - AVROBIO (AVR-RD-04), Birch Therapeutics, Nacuity Pharmaceuticals, Horizon Pharma, Recordati

As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Cystinosis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Cystinosis Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cystinosis Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Cystinosis Pipeline Analysis
The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Cystinosis Market.

The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystinosis treatment.

It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cystinosis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Key Developments in the Cystinosis Therapeutics Market
On September 20, 2022, AVROBIO, Inc. (Nasdaq: AVRO) announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to its investigational gene therapy for the treatment of cystinosis, AVR-RD-04. AVR-RD-04 is designed to genetically modify patients' own hematopoietic stem cells (HSCs) to express the gene encoding cystinosis.

Cystinosis Therapeutics Analysis
There are approx. 5+ key companies developing therapies for Cystinosis. Currently, AVROBIO has its Cystinosis drug candidates in the most advanced stage of clinical development.

Some of the Major Players in the Cystinosis Therapeutics Market include:
• AVROBIO
• Birch Therapeutics
• Nacuity Pharmaceuticals
• Horizon Pharma
• Recordati S.p.A.
• Leadiant Biosciences
• Mylan Pharmaceuticals
• Eloxx Pharmaceuticals
And many others

DelveInsight's Report covers around 5+ products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cystinosis Emerging Drugs Covered in the report include:
• AVR RD 04
• NP-3
• ELX-02
• A0003
• Procysbi (cysteamine bitartrate)
• Cystadrops (cysteamine hydrochloride)
• Cystaran (cysteamine hydrochloride)
• Cystagon (cysteamine bitartrate)
And many more

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Cystinosis Current Treatment Patterns
4. Cystinosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cystinosis Late Stage Products (Phase-III)
7. Cystinosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cystinosis Discontinued Products
13. Cystinosis Product Profiles
14. Cystinosis Key Companies
15. Cystinosis Key Products
16. Dormant and Discontinued Products
17. Cystinosis Unmet Needs
18. Cystinosis Future Perspectives
19. Cystinosis Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/cystinosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.